Previous 10 | Next 10 |
2024-05-28 10:23:08 ET More on Gilead Sciences Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors ...
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Gilead Sciences: In an effort to advance access to cancer prevention and early detection among U.S. workers, the Biden Cancer Moonshot recently announced a series of actions that organizations are taking to improve access and use of cancer screeni...
2024-05-28 09:45:00 ET Equities never follow a flawless, unimpeded upward path. Sometimes, even the strongest companies will encounter issues that will sink their stock prices. That's OK. The key to earning great returns over five years or more is sticking with those longtime winners, even ...
2024-05-27 13:07:50 ET Summary At this point, Gilead Sciences could only be fairly valued with trading for 10 times free cash flow. With Veklury sales close to a bottom, Gilead Sciences might finally start growing its top line again - acquisition might also contribute to growth. ...
2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...
2024-05-26 05:30:00 ET Summary Parnassus Investments is a fundamental, bottoms-up investment firm offering responsible investment funds to the public. Parnassus Investments integrates comprehensive ESG evaluations with fundamental financial analysis to select investments. The Fund...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
2024-05-24 15:00:53 ET More on the markets S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards Stocks have more room to run - Invesco's Kristina Hooper Big bear Mike Wilson changes tune a...
2024-05-24 06:05:00 ET Summary Dodge & Cox Stock Fund seeks long-term growth of principal and income, with a secondary focus on achieving a reasonable current income. U.S. equity markets rose to all-time highs during the first quarter of 2024, extending the robust perform...
2024-05-23 07:00:00 ET Summary Gilead Sciences has a 4.5% yield. The company has struggled with declining profits and sales in recent years. The company's growth potential lies in its HIV and oncology treatments, but it faces competition and disappointing trial results. Gilead...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...